Status:
COMPLETED
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan
Lead Sponsor:
Addpharma Inc.
Conditions:
Hypercholesterolemia
Hypertension
Eligibility:
All Genders
19+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and essential hypertension.
Detailed Description
This trial is a phase 3 study to evaluate efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and essential hypertension. In "...
Eligibility Criteria
Inclusion
- Signed informed consent
- Subjects with hypertension and hyperlipidemia
Exclusion
- Patient with known or suspected secondary hypertension
- Other exclusions applied
Key Trial Info
Start Date :
February 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 12 2020
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03872232
Start Date
February 26 2019
End Date
August 12 2020
Last Update
January 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080